Last €17.47 EUR
Change Today -0.14 / -0.80%
Volume 0.0
QL1 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 10:45 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

quidel corp (QL1) Snapshot

Open
€17.36
Previous Close
€17.61
Day High
€17.47
Day Low
€17.30
52 Week High
01/17/14 - €23.08
52 Week Low
04/25/13 - €15.35
Market Cap
597.6M
Average Volume 10 Days
15.0
EPS TTM
--
Shares Outstanding
34.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QUIDEL CORP (QL1)

Related News

No related news articles were found.

quidel corp (QL1) Related Businessweek News

No Related Businessweek News Found

quidel corp (QL1) Details

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, women’s health, and gastrointestinal diseases. The company offers Sofia analyzer, a fluorescent immunoassay system for hospitals, medical centers, and small clinics; various molecular assays, which run on thermocyclers; Sofia influenza A+B and QuickVue influenza tests for the detection of the viral antigens of influenza type A and B; and Sofia strep A fluorescent immunoassay and QuickVue Strep A tests for the detection of group A Streptococcal antigen from throat swabs. It also provides Sofia RSV and QuickVue RSV tests for respiratory syncytial virus; cell culture and DFA detection solutions for the detection of various viral respiratory pathogens; and various traditional cell lines, specimen collection devices, media, and controls for the use in laboratories. In addition, the company offers ELVIS HSV, a cell culture system for the isolation and detection of herpes simplex virus types 1 and 2; and multiplex cell culture solution. Further, it provides Quidel Molecular Direct clostridium difficile assay; Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests, which are used for the detection of hCG in serum or urine for the early detection of pregnancy; Thyretain for the differential diagnosis of Graves disease; and QuickVue Chlamydia test for the detection of Chlamydia trachomatis. Additionally, the company offers QuickVue test, a fecal immunochemical test to detect the presence of blood in stool specimens; indirect fluorescent antibody products; serological test that measures antibodies circulating in the blood; and diagnostic and research products for oncology, bone health, and autoimmune diseases. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.

572 Employees
Last Reported Date: 02/27/14
Founded in 1979

quidel corp (QL1) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $509.1K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $313.2K
Senior Vice President of Commercial Operation...
Total Annual Compensation: $307.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $297.5K
Senior Vice President of Business Development...
Total Annual Compensation: $329.0K
Compensation as of Fiscal Year 2013.

quidel corp (QL1) Key Developments

Quidel Corporation Receives FDA Clearance for its AmpliVue(R) Hand-Held Molecular Diagnostic Test for Herpes Simplex Virus Types 1 and 2

Quidel Corporation announced that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for the sale of its AmpliVue HSV 1+2 Assay for the differentiation and detection of herpes simplex viruses 1 and 2. The AmpliVue HSV 1+2 Assay is easy-to-use, handheld and disposable. The assay requires no upfront extraction of DNA and generates an accurate result in approximately one hour. Like other previously FDA-cleared AmpliVue assays, the AmpliVue HSV 1+2 Assay does not require investment in expensive thermocycling equipment. Using AmpliVue can therefore significantly lower a laboratory's cost to adopt and maintain molecular testing methods. The AmpliVue product line now enables laboratories of all sizes to perform highly sensitive and specific molecular tests for four pathogens -- two viruses and two bacterial species -- without incurring the significant expense that is usually required to adopt and maintain molecular testing methods on-site. The AmpliVue HSV 1+2 is Quidel's third assay to launch in its hand-held, disposable format. The AmpliVue C. difficile assay for the molecular detection of toxigenic Clostridium difficile bacterial DNA received FDA clearance in December of 2012. The AmpliVue GBS Assay for the molecular detection of Group B Streptococcus infections received FDA clearance in December of 2013. All three assays are now available for sale throughout the U.S. and Europe, with several other assays currently in development.

Quidel Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Effective Tax Rate Guidance for the Year 2014

Quidel Corp. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company's total revenues were $50,170,000 compared to $53,925,000 a year ago. The decrease in revenue was due to lower sales of infectious disease products in the quarter, driven primarily by a more normalized influenza and respiratory disease season in 2013 as compared to an earlier and more severe season in the prior year. Operating income was $67,000 compared to $14,117,000 a year ago. Loss before taxes was $89,000 compared to income before taxes of $13,859,000 a year ago. Net income was $1,139,000 or $0.03 per basic and diluted share compared to $8,740,000 or $0.26 per basic and diluted share a year ago. Adjusted net income was $6,964,000 or $0.20 per diluted share compared to $12,497,000 or $0.37 per diluted share a year ago. For the year, the company's total revenues were $175,410,000 compared to $155,741,000 a year ago. Operating income was $4,165,000 compared to $8,846,000 a year ago. Income before taxes was $3,434,000 compared to $7,611,000 a year ago. Net income was $7,390,000 or $0.21 per diluted share compared to $4,993,000 or $0.15 per basic and diluted share a year ago. Adjusted net income was $21,348,000 or $0.61 per diluted share compared to $19,062,000 or $0.56 per diluted share a year ago. The company generated approximately $26 million in cash from operating activities, spent approximately $20.8 million in capital expenditures. For 2014, the company estimates effective tax rate to be in the range of 34% to 36%, excluding the impact of any non-discrete tax issues and without consideration for the 2014 research and development tax credit, which has not yet been approved by Congress.

Quidel Corp. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-03-2014 04:10 PM

Quidel Corp. Presents at Cowen & Co. 34th Annual Health Care Conference, Mar-03-2014 04:10 PM. Venue: Marriott Copley Place Hotel, Boston, Massachusetts, United States. Speakers: Douglas C. Bryant, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QL1:GR €17.47 EUR -0.14

QL1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ion Beam Applications €9.52 EUR -0.28
Meridian Bioscience Inc $21.82 USD +0.34
Nanosphere Inc $1.83 USD -0.02
OraSure Technologies Inc $6.92 USD +0.25
Response Biomedical Corp C$1.50 CAD -0.07
View Industry Companies
 

Industry Analysis

QL1

Industry Average

Valuation QL1 Industry Range
Price/Earnings 100.0x
Price/Sales 4.8x
Price/Book 3.7x
Price/Cash Flow 53.7x
TEV/Sales 4.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUIDEL CORP, please visit www.quidel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.